In the updated expansion cohort data from the RESTORE trial of elritercept plus ruxolitinib in anemic patients with myelofibrosis, what average hemoglobin increase from baseline was reported?
Approximately 0.5 g/dL
Approximately 1.5 g/dL
Approximately 3.0 g/dL